Intersect ENT was a Menlo Park, California-based medical device company that developed and commercialized drug-eluting sinus implants, including the PROPEL and SINUVA products, designed to improve outcomes for ENT surgical patients. Founded in 2003, it was publicly traded before being acquired by Medtronic in May 2022 for approximately $1.1 billion.
Create a free account to see funding visualizations and detailed round data.
Create Free AccountCreate a free account to see full funding history, valuations, and investor participation.
Create Free AccountCreate a free account to see which investors have funded this company.